BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 7, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: House passes H.R. 1, restoring R&D tax cutsBreaking News: Self-amplifying mRNA technology underscored for next big pandemic
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins, pathogens and certain trafficking cells. Among these harmful substances are deleterious factors associated with aging, which can prematurely damage different tissues. The big question is what are those factors that mediate such effects, and what can be done to prevent them. The 11th Cardiac Regeneration and Vascular Biology Conference, held on the Island of San Servolo, Venice, from June 30 to July 2, 2025, included presentations, oral sessions and posters addressing the impact of aging on the cardiovascular system.
  • Chemotherapy-induced mutations are not universal phenomenon

    The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not all, of these agents cause mutations and premature aging of normal blood cells.
  • At CRVBC 2025: Aging is circulating in your blood

    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins, pathogens and certain trafficking cells. Among these harmful substances are deleterious factors associated with aging, which can prematurely damage different tissues. The big question is what are those factors that mediate such effects, and what can be done to prevent them. The 11th Cardiac Regeneration and Vascular Biology Conference, held on the Island of San Servolo, Venice, from June 30 to July 2, 2025, included presentations, oral sessions and posters addressing the impact of aging on the cardiovascular system.
  • Chemotherapy-induced mutations are not universal phenomenon

    The first systematic whole genome sequencing study of how chemotherapy damages healthy tissues has shown that many, but not all, of these agents cause mutations and premature aging of normal blood cells.
  • Other news to note for July 4, 2025

    Additional early-stage research and drug discovery news in brief.
  • Brightpath’s BP-2202 designated orphan drug for multiple myeloma

    Brightpath Biotherapeutics Co. Ltd.’s iPS cell-derived BCMA CAR-natural killer T cell therapy candidate has been awarded orphan drug designation by the FDA for the treatment of multiple myeloma.
  • Innocare’s ICP-B794 gains IND clearance in China

    Innocare Pharma Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of the B7-H3 targeted antibody-drug conjugate.
  • Jiangsu Vcare Pharmatech patents new ER degradation inducers

    Jiangsu Vcare Pharmatech Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor (ER) degradation inducers.
  • IL-24S/IL-15 fusion ‘superkine’ induces apoptosis of GBM cells, promotes antitumor immunity

    A recent study published in the Journal for Immunotherapy of Cancer has revealed a promising new approach for the treatment of glioblastoma (GBM), an aggressive and incurable form of primary brain cancer.
  • Insparin, a promising antidiabetic peptide

    Peptide illustration
  • Vanderbilt University divulges new muscarinic M4 receptor PAMs

  • Zhuhai Yufan Biotechnologies describes new IKZF1 degradation inducers

  • Insights into OXA1L deficiency and mitochondrial myopathy

    Mitochondria
  • New MRGPRX2 antagonists disclosed in Humanwell Healthcare patent

  • Shanghai Curegene Pharmaceutical discovers new nucleoside prodrugs for viral infections

  • CYT-997 could be new approach for treating hypertrophic scars

    Fibroblast illustration

BioWorld Insider Podcast

Play buttonRobert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.
Listen now

Conferences

  • Pills, bottle, scale and-measuring tape

    Eccogene’s ECC-4703 leads to greater weight loss in preclinical studies

    American Diabetes Association
    Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an agonist of thyroid hormone receptor β (THR-β) and its metabolic impact on preclinical models of obesity...
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    [68Ga]NXK-44 radiotracer arises as a promising agent for RCC

    New compound
    Chinese researchers from Huazhong University of Science and Technology have developed a novel carbonic anhydrase IX (CAIX)-targeting radiotracer, [68Ga]NXK-44, for the imaging of hypoxic tumors and renal cell carcinoma (RCC).
  • 3D illustration of transparent human torso with close up of spinal cord

    GRWD-0715 blocks pathogenic T-cell activation in axial spondyloarthritis

    Musculoskeletal
    Researchers from Grey Wolf Therapeutics Ltd. presented the preclinical characterization of GRWD-0715, a selective ERAP1 inhibitor developed as a disease-modifying therapeutic approach aimed at preventing CD8+ T-cell activation and the subsequent tissue inflammation and damage associated with...
  • Woman measuring her body fat with caliper

    ASC-47 shows superior weight loss effect compared to semaglutide

    American Diabetes Association
    ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in healthy subjects and in patients with obesity, respectively.
More in Conferences

Today's news in brief

  • Other news to note for July 4, 2025

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • Scientists in Spain discover new senolytic compounds

  • 5-HT2A receptor agonists disclosed in Xylo patent

  • Incurix describes new c-Myc inhibitors

  • Merck KGaA divulges new YAP1/TEAD and TAZ/TEAD interaction inhibitors

  • Japanese scientists patent new compounds for HCV infection

  • Pfizer discovers new KAT2A and KAT2B inhibitors

  • New GPR40 agonists disclosed in Cascade Pharmaceuticals patent

  • Kestrel Therapeutics describes new GTPase KRAS inhibitors

  • Euregen Biopharma divulges new Mat2A inhibitors

  • Hungarian scientists patent new potassium channel blockers

Cancer

  • Concept art for "cancer cells destroyed by oncogenic virus"

    IL-12-expressing oncolytic virus shows promise for solid tumors

    Immuno-oncology
    A newly developed oncolytic virus, SKV-012, has demonstrated promising results in preclinical studies and a phase I clinical trial for the treatment of advanced solid tumors.
  • A genipin derivative that may combat triple-negative breast cancer by stimulating ferroptosis

  • Preclinical results of first-in-class PTK7-targeted radionuclide therapy in ovarian cancer

  • Boehringer Ingelheim selects new oncology drug candidate from Oxford Biotherapeutics collaboration

    Collaboration
  • Researchers arm CAR T cells to fight solid tumors

    Drug design, drug delivery and technologies
More in Cancer

Infection

  • Digital lungs illustration

    Bioversys, Shionogi in CHF529M lung infection collaboration

    Clinical
    Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
  • Pfizer discovers new nucleoprotein N inhibitors for RSV infection

    Patents
    Pfizer Inc. has described nucleoprotein N (respiratory syncytial virus [RSV]) inhibitors reported to be useful for the treatment of RSV infection.
  • New PZA-mimicking prodrugs for tuberculosis disclosed in University of Maryland patent

    Patents
    University of Maryland has divulged pyrazinamide (PZA)-mimicking prodrugs reported to be useful for the treatment of tuberculosis.
  • French scientists describe new treatment for cryptosporidiosis

    Patents
  • Shemyakin Institute of Bioorganic Chemistry divulges new antiviral photosensitizers for SARS-CoV-2

    Coronavirus
  • Discovery and evaluation of new indole-dihydropyrimidinone derivatives for visceral leishmaniasis

  • French researchers identify new agents for tuberculosis

    Patents
More in Infection

Neurology/psychiatric

  • Nervous system illustration

    Redox-sensitive PET tracer detects ROS-driven neuroinflammation

    Conferences
    Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter probe for imaging neuroinflammation in preclinical models of multiple sclerosis (MS). MS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by...
  • Shenzhen Bay Laboratory divulges new GPR139 agonists

    Patents
    Shenzhen Bay Laboratory has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of Parkinson’s disease, epilepsy, pain, depression, schizophrenia, substance abuse and dependence, post-traumatic stress and autism spectrum disorders.
  • Valo Health patents new S1P1 receptor agonists

    Patents
    Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis, systemic lupus erythematosus, ulcerative colitis, lymphopenia and Crohn’s disease.
  • MRT-6160 VAV1 molecular glue blocks EAE in preclinical models

    Conferences
    VAV1 is a guanine nucleotide exchange factor essential for T- and B-cell receptor signaling, with expression largely restricted to immune cells. Loss of VAV1, via CRISPR or genetic deletion, impairs effector functions in both T and B cells.
  • Tree in the shape of human head losing leaves

    Encoding an entire mAb against TDP-43 into AAV to treat neurodegenerative diseases

    Monoclonal antibody
    Monoclonal antibodies show strong therapeutic potential against neurodegenerative diseases, but a major challenge is ensuring that they can arrive unharmed in the brain at sufficient concentrations. One way around this challenge is to vectorize the monoclonal antibody: encode it within a vector...
More in Neurology/psychiatric

Immune

  • Unnatural Products joins Argenx in a $1.5B macrocyclic deal

  • Immune checkpoint enhancer ALTB-268 decreases inflammation

  • CRVBC: Cardiac diseases can start in utero after immune migration

  • Sanofi to advance KT-485 into clinic under IRAK-4 partnership with Kymera

  • Evaxion unveils new vaccine program to prevent group A Streptococcus infections

  • Immunoproteasome triggers neurodegeneration in multiple sclerosis

  • EAN 2025: CAR T cells take on neurological disorders, though sometimes still one patient at a time

  • Rubedo Life Sciences patents new Bcl-xl inhibitors

  • Cue Biopharma holds pre-IND meeting with FDA for lead autoimmune asset

  • CEPI-backed consortium to develop all-in-one filovirus vaccine

Endocrine/metabolic

  • Feet on scale and measuring tape

    Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity

    Peptide
    Protagonist Therapeutics Inc. has nominated PN-477 as a development candidate for the treatment of obesity.
  • BI-4659 reverses diet-induced obesity in mice

    Conferences
  • TLC-1180 supports durable weight loss and metabolic gains in combination approaches

    Conferences
  • SKNY-1 demonstrates weight loss and reverses nicotine-seeking behavior in zebrafish

    Substance use and poisoning
  • Abvance Therapeutics secures seed funding to limit glucose lows

    Financings
More in Endocrine/metabolic

Biomarkers

  • Xray showing lung cancer on tablet

    Metabolic markers to predict efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

    Cancer
    Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of lung cancer involve non-small-cell lung cancer (NSCLC), in which therapy with immune checkpoint inhibitors (ICIs) can improve prognosis, yet up to 75% of patients fail to...
  • miR-7974 is a predictor of poor survival in ER+ breast cancer

    Conferences
    Estrogen receptor-positive (ER+) breast cancer remains a major challenge even with well-defined treatment options. The identification of reliable markers for early detection of the disease is crucial for improving patient outcomes.
  • Taurine aging biomarker story gets more complicated

    Science
    A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on Aging published on June 5, 2025, in Science has stated that the impact of taurine supplementation at delaying aging or treating aging-related conditions is context-dependent,...
  • MCTP2 induces oral cancer progression and metastasis

    Cancer
  • FFAR4 as biomarker of glomerular injury and aging

    Aging
  • Stress sensor inhibition ameliorates Alzheimer's pathology in mice

    Neurology/psychiatric
  • Pan-cancer proteome atlas reveals new biomarkers and targets

    Cancer
More in Biomarkers

Gastrointestinal

  • Engineered anti-IL-23 receptor antibody enables oral delivery to treat inflammatory bowel disease

    Antibody
    Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel disease in animal models.
  • Gut microbiome leads to metabolic and immune changes after transplant

    Science
    Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
  • Korean scientists divulge new ADAMTS4 inhibitors for hepatic fibrosis

    Patents
    Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
  • New LPAM-1 antagonists disclosed in Dice Molecules patent

    Patents
    Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
  • Gut microbiome leads to metabolic and immune changes after transplant

    Science
    Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions to analyze the...
  • 17β-HSD13 inhibitors described in Astrazeneca patent

    Patents
    Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others.
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • The importance of balancing AI and people in drug development
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO
  • Capricor’s CEO pursues a BLA and talks rare disease
  • The first half of 2024 was strong as M&As and financings dominate

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing